BioSpace News Archive

Drug Development

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

4D Molecular Therapeutics announced positive interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration patients with severe disease activity and a high treatment burden.

February 3, 2024
·
12 min read
Drug Development

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals, Inc. announced results from new subgroup analyses from the Phase 2 DAVIO 2 clinical trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E.

February 3, 2024
·
10 min read